Proton Pump Inhibitors Linked to Higher Asthma Risks
New research suggests a correlation between acid reflux medication and increased asthma exacerbations.
Updated on Oct. 20, 2026 in Asthma
Live Poll
Do you worry about the long-term health risks of taking daily acid-suppressing medication?
A study presented at the CHEST Annual Meeting found that asthma patients taking proton pump inhibitors face higher rates of exacerbations and hospitalizations. The data suggests these medications may negatively impact outcomes for patients already receiving biologics.
Why it matters
Long-term acid suppression therapy could alter the microbiome, potentially increasing patient vulnerability to respiratory pathogens. These findings highlight the need for careful medication management in complex asthma cases.
The study utilized a cohort of 1,228 patients per group to compare health outcomes. Researchers observed that 72% of PPI users required systemic corticosteroids, significantly higher than the 40% requirement among nonusers.
The players
CHEST
This is a professional organization dedicated to the prevention, diagnosis, and treatment of chest diseases through education and research.
TriNetX
This global health research network provides access to anonymized electronic health records for clinical study and medical analysis.
The details
Using the TriNetX U.S. Collaborative Network, researchers analyzed health records of adults on biologics between 2014 and 2025. The analysis showed PPI users experienced respiratory infections at a rate of 8.4%, compared to just 2.3% for those not taking the medication.
Timeline
2014-2025: Study period for asthma patients treated with biologics.
October 2026: Presentation of research at the CHEST Annual Meeting.
Health Landscape
This study follows a pattern of utilizing the TriNetX U.S. Collaborative Network to identify previously unlinked health risks in large patient populations. It underscores the growing reliance on massive electronic health record datasets to shape modern clinical guidelines.
Patients using both biologics for asthma and proton pump inhibitors should discuss these findings with their healthcare provider to evaluate their current treatment regimen. Monitoring for increased respiratory symptoms may be necessary for those requiring long-term acid suppression therapy.
The takeaway
Patients should not discontinue prescribed medications without medical consultation despite these findings. Continued monitoring of side effects and respiratory health remains the most effective approach for those with chronic asthma.
Further reading
Learn more about managing complex respiratory conditions in the Asthma section.
Source note: This article includes information reported by Healio.
Live Poll
Do you worry about the long-term health risks of taking daily acid-suppressing medication?
